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Abstract
Background: The extent to which mental and physical exercise may slow cognitive decline in adults with early signs
of cognitive impairment is unknown. This article provides the rationale and methodology of the first trial to investigate
the isolated and combined effects of cognitive training (CT) and progressive resistance training (PRT) on general
cognitive function and functional independence in older adults with early cognitive impairment: Study of Mental and
Regular Training (SMART). Our secondary aim is to quantify the differential adaptations to these interventions in terms
of brain morphology and function, cardiovascular and metabolic function, exercise capacity, psychological state and
body composition, to identify the potential mechanisms of benefit and broader health status effects.
Methods: SMART is a double-blind randomized, double sham-controlled trial. One hundred and thirty-two community-
dwelling volunteers will be recruited. Primary inclusion criteria are: at risk for cognitive decline as defined by
neuropsychology assessment, low physical activity levels, stable disease, and age over 55 years. The two active
interventions are computerized CT and whole body, high intensity PRT. The two sham interventions are educational
videos and seated calisthenics. Participants are randomized into 1 of 4 supervised training groups (2 d/wk × 6 mo) in a
fully factorial design. Primary outcomes measured at baseline, 6, and 18 months are the Alzheimer’s Disease Assessment
Scale (ADAS-Cog), neuropsychological test scores, and Bayer Informant Instrumental Activities of Daily Living (B-IADLs).
Secondary outcomes are psychological well-being, quality of life, cardiovascular and musculoskeletal function, body
composition, insulin resistance, systemic inflammation and anabolic/neurotrophic hormones, and brain morphology
and function via Magnetic Resonance Imaging (MRI) and Spectroscopy (fMRS).
Discussion: SMART will provide a novel evaluation of the immediate and long term benefits of CT, PRT, and
combined CT and PRT on global cognitive function and brain morphology, as well as potential underlying
mechanisms of adaptation in older adults at risk of further cognitive decline.
Trial Registration: Australia and New Zealand Clinical Trials Register (ANZCTR): ANZCTRN12608000489392
Background
With a forecast 100 million persons with dementia by
2050, this disorder presents a major challenge to suf-
ferers, their caregivers, and the health care system, and
delay of disease onset and progression is amongst the
most pressing challenges for medical research [1]. A
five-year delay in dementia onset and progression could
halve disease prevalence [2] and would have a significant
impact on disease burden. The efficacy of pharmacologi-
cal treatments to date have been limited to symptom
control [3] and have not been effective in reducing dis-
ease onset, and so non-pharmacological preventative
interventions are of great interest.
There is strong evidence from cross-sectional and pro-
spective cohort studies that participation in mentally
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any medium, provided the original work is properly cited.and physically stimulating activities is associated with
decreased dementia prevalence and/or incidence [4-9].
Experimental trials indicate that cognitive training can
significantly improve performance in healthy adults on a
range of cognitive tasks, with an average moderate effect
size (ES) of 0.6 [10-13]; and that exercise interventions
of as little as one week of aerobic exercise can result in
improved memory, attention, and reaction time [14].
Sustained improvements, particularly in executive func-
tion, have been shown after aerobic training (ES = 0.41),
combined aerobic and resistance training (ES = 0.59),
and resistance training alone (ES = 0.53), even after
exercise was withdrawn in some cases [15].
Two studies to directly compare single and combined
physical and mental exercise found effect sizes across a
range of cognitive outcomes to be much larger in the
combined condition [12,16]. Both of these studies had
design flaws, including very small sample sizes [16] and
high dropout rates [12], limiting conclusions. Therefore,
a robustly designed trial is required to investigate the
comparative benefits of isolated and combined physical
and mental training.
The mechanisms of benefit from physical and mental
interventions are not clear, it has been postulated that
physical and mental activity may therefore have poten-
tial to stimulate plasticity of the brain and possibly
reduce dementia onset. Animal studies have demon-
strated a range of positive neurobiological outcomes,
including decreased inflammatory cytokines, decreased
cortisol response to stressors, increased insulin-like
growth factor-1 (IGF-1) into the brain, increased cere-
bral blood flow and angiogenesis, and increased hippo-
campal volume, brain derived neurotrophic factor
(BDNF), neurogenesis, and synaptic density after mem-
ory-enhancing cognitive and exercise training [7,17].
Human data are more limited, but observations of
responses to training have included increased blood
flow, aerobic capacity, and region brain volume after
behavioural and aerobic training [18,19] and improved
brain chemistry using magnetic resonance spectrometry
(MRS) in our pilot work with cognitive training [20].
There are fewer human data available on the possible
cognitive-enhancing mechanisms of resistance training,
with findings of no changes in BDNF [21], and increases
in IGF-1 [22]. Animal and human exercise trials indicate
that exercise may improve brain function via two path-
ways; directly through the induction and regulation of
growth factors (e.g., BDNF, IGF-1), and/or indirectly via
the modulation of systemic inflammation [7]. However,
rigorous clinical trials investigating the central and per-
ipheral synergistic benefits of exercise for improved
b r a i nf u n c t i o na r el a c k i n g[ 7 ] .C o n s e q u e n t l yt h eS t u d y
of Mental Activity and Regime Training trial (SMART)
was designed and implemented to examine the isolated
and combined benefits of cognitive training and resis-
tance training, and to provide novel, comprehensive
data on possible proposed links between cognitive
improvement and brain and whole-body-adaptation to
resistance and cognitive training.
Most cognitive and exercise training trials have tar-
geted healthy, cognitively intact adults. The most vul-
nerable individuals at highest risk for cognitive decline,
however, are those with early cognitive impairment
and co-morbid diseases such as cardiovascular disease,
type 2 diabetes, obesity, and hypertension (i.e. meta-
bolic syndrome). We are therefore deliberately exclud-
ing high functioning volunteers and targeting a highly
clinically relevant population, with evidence of early
cognitive impairment and various cardiovascular risk
factors. These individuals may not be capable of the
moderate or high intensity aerobic training that has
been shown to be effective in animal and human trials.
Resistance training, which has a larger effect size in
the literature (0.53) than isolated aerobic training
(0.41), and comparable to combined aerobic/resistance
training (0.59), may be a more realistic exercise option
i nt h i sc o h o r t ,a si ti sm o r ef e a s i b l ei ne l d e r sw i t h
frailty and mobility impairment, thus having the poten-
tial for long-term adherence. We [23] and others have
shown that resistance training results in many benefi-
cial adaptations in older adults that may be relevant to
the mechanisms underlying its putative cognitive bene-
fits. These adaptations (see Figure 1), many of which
will be studied in this proposal (particularly changes in
fitness, inflammation, and body composition) would
not be anticipated after exposure to cognitive training
alone, consequently the SMART trial will enable inves-
tigation of the efficacy of combining these two dis-
tinctly different training paradigms.
The SMART trial is a long term study that will mea-
sure evidence of both immediate and sustained benefits
of training, one year after withdrawal of active treat-
ment. In addition to the selection of general cognitive,
functional, physical, mood symptoms and quality of life
outcome measures will also be assessed to identify the
extent of transfer of benefits of our interventions.
Objectives and Hypothesis
The primary objective of the SMART trial is to deter-
mine whether cognitive, physical or combined cognitive
and physical training can prevent or slow cognitive and
functional decline in vulnerable older adults at high risk
of dementia. Our secondary aim is to explore adaptation
to these two interventions in the brain, as well as iden-
tify potential mechanisms of benefit, in particular modu-
lation of cardiovascular risk profile, systemic
inflammatory cytokines, growth factors, fitness levels,
and body composition.
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1. Six months of supervised cognitive training (CT) will
significantly improve cognitive function, as assessed by
the Alzheimer’s Disease Assessment Scale Cognitive
subscale (ADAS-Cog) [24,25], and independence of
function as assessed by the Bayer Informant -Activities
of Daily Living (BIADL) [26] at both 6- and 18- month
follow-up, relative to a sham training control condition.
2. Six months of supervised high intensity progressive
resistance training (PRT) will significantly improve cog-
nitive function, as assessed by the ADAS-Cog, and inde-
pendence of function as assessed by the Bayer
Figure 1 Theoretical model of mechanisms linkage between progressive resistance training, cognitive training, and cognitive and
functional outcomes. BDNF = brain-derived neural growth factor IGF-1 = insulin-like growth factor-1.
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and 18-month follow-up, relative to a sham training
control condition.
3. The combination of CT and PRT will be signifi-
cantly superior to either intervention in isolation for
cognitive and functional benefits.
Secondary Hypotheses
1. All active training interventions will improve brain
morphology and biochemistry compared to the sham
control condition, as defined by: increased hippocampal
volume (mm
3) by MRI scanning; positive localised
Voxel-Based Morphometry (VBM) brain changes (z-
s c o r er e l a t i v ec h a n g e ) ;d e c r e a s e dw h o l eb r a i nv o l u m eo f
White Matter Hyper-intensities (WMHs) (mm
3); and
lead to beneficial hippocampal and posterior cingulate
MRS metabolite changes (% increase in N-acetylaspar-
tate, and increase in phosphocreatine metabolites).
2. All active training interventions will improve sec-
ondary cognitive outcomes, in the domains of attention,
memory, fluency, and executive function, relative to the
sham control condition, and combined training will be
superior to either single intervention.
3. All active training interventions will maintain global
clinical impression scores, as defined by the Clinical
Dementia Rating (CDR) scale, relative to the sham con-
trol condition.
4. PRT exercise will preferentially decrease inflamma-
tory markers, insulin resistance, and central adiposity
and increase fitness (strength and aerobic capacity),
muscle mass, and functional mobility, compared to
either cognitive or sham control condition.
5. Cognitive and physical training will produce positive
effects on psychological health and quality of life above
and beyond the non-specific effects seen after sham
control condition.
Methods
Study Design and Setting
The SMART trial is a longitudinal double-blind, sham
training-controlled, randomized clinical trial adhering
precisely to CONSORT guidelines http://www.consort-
statement.org for the conduct and reporting of clinical
trials, as extended to non-pharmacological interventions
[27]. Ethical approval was obtained from the Sydney
South West Area Health Service (HREC Ref.08/RPAH/
106), University of Sydney Human Research Ethics
(HREC: 06-2008/11094), University of New South Wales
(HREC: 08152), and signed informed consent was
obtained from all participants. Participants are from the
greater Sydney metropolitan area, and the study is con-
ducted at Cumberland Campus of the University of Syd-
ney in Lidcombe NSW Australia. MRI scans are
performed at the Clinical Research Imaging Centre in
Randwick NSW Australia.
Study Population and Eligibility Criteria
Participants are community-dwelling persons aged 55 or
above, with primary inclusion criteria being self-reported
memory complaint, a Clinical Dementia Rating (CDR)
[28] of ≤ 1.0; Mini-Mental Status Examination (MMSE)
[29] score of 23-29; and willing to have multiple cogni-
tive, physical and imaging assessments over 18 months.
Complete inclusion and exclusion criteria are listed in
Table 1.
Recruitment
Participants are to be recruited from October 2008 until
December 2011 from media publicity on state radio,
advertisements in local newspapers and businesses, a
mail campaign using the electoral roll, contact with par-
ticipants from previous studies who provided consent
for such contact, general practitioner lists, aged care and
health service facilities, community programs for seniors
and word of mouth.
Sample size estimates
Sample size estimates (alpha 0.05, beta 0.20) are based
on planned comparisons for the main effects of PRT
and CT, as well as the effect of combined training vs.
either intervention in isolation on our primary outcome:
global cognitive function as assessed by ADAS-Cog. The
assumptions are as follows: our meta-analyses [30] and
review of published RCTs in older adults [15] reveal
Effect Sizes (ES) for a range of cognitive outcomes of
approximately 0.60 for cognitive training, 0.59 for aero-
bic/resistance training, and 0.53 for resistance training,
compared to 0.15 for control groups. However, as we
are enrolling a cohort with early cognitive impairment,
we anticipate a decline of approximately this magnitude
(ES = 0.15) over 12 months in our sample, so that the
sham control condition would merely offset that decline
(ES = 0.0). Thus, we have conservatively powered the
study to show an ES of 0.53 for the main effects of both
CT and PRT vs. control (n rounded up to 30/group × 4
= 120 required for 4-cell factorial design).
The only two published studies of combined mental
and physical training [12,16] showed average ES = 0.94
for combined training compared to mental training
alone and ES = 1.27 for combined training compared to
exercise training alone. Therefore, we have ample power
(99.7%) to find a difference of this magnitude between
o u rc o m b i n e dt r a i n i n g( n=3 0 )a n di s o l a t e dt r a i n i n g
groups (n = 30). Reported dropout from drug trials in
MCI is 28% [31] however our experience in fully super-
vised training of older adults with frailty/chronic disease
dropout averages 10-15% over 12 months. Therefore, we
will inflate sample size needs for approximately10%
drop out rate to account for anticipated attrition (n =
132), and we will recalculate these sample size needs in
interim analysis after the first 50 participants have
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sample size needs if required.
Screening procedure
Potential participants undergo initial telephone interview
and screening using the 13-item modified Telephone
Interview for Cognitive Status (TICS-M) [32], inclusion
score between 21-30/39 to exclude high cognitively
functioning individuals. Health status and lifestyle beha-
viours are also assessed via telephone. Informants are
interviewed using the Bayer-Activities of Daily Living
(B-IADL) [26], Informant KATZ Index of ADL [33], and
informant ratings of memory decline and concern. A
subset of informants complete an in-person B-IADL
form to validate the telephone version.
Participants provide signed informed consent prior to
completing a series of in-person screening assessments.
A flow of assessment procedures is presented in Figure
2. A structured clinical interview including psychiatric
screening is completed by a neuropsychologist, and
CDR score is calculated prior to physician and physical
screening. If eligible after physician screening, the
remainder of the baseline physical performance testing
is completed, followed by baseline cognitive tests and
MRI scan. If following screening a participant was
excluded for low vitamin D, acute illness, or abnormal
stress test or raised blood pressure, he or she may enter
the study following appropriate treatment and medical
review. Participants are randomised at the completion of
all baseline assessments.
Randomisation, concealment, and allocation
A concealed, computer-generated sequence of randomly
permuted blocks (block size = 8), stratified by gender
and age, is generated by a statistician not otherwise
involved in the study (http://www.randomization.com,
created by Dr Gerard E. Dallal, Tufts University). Ran-
domization occurs at the completion of the entire base-
line assessment. Where randomization occurs in person,
assignments will be placed in sealed opaque envelopes
and delivered to subjects by the recruitment officer with
subjects designated to 6 months of cognitive training,
progressive resistance training, combined cognitive and
Table 1 Inclusion and exclusion criteria for the SMART trial
Inclusion criteria Exclusion criteria
Age ≥ 55
Competency in English sufficient for assessment and training
Community-dwelling
MMSE^ 23-29
CDR^^ ≤ 1.0
TICS
#<3 0
No unstable disease precluding planned exercise*
Absence of significant cognitive decline in 5 years
Absence of known organic or psychiatric condition affecting
cognition
Able to see and hear sufficiently to participate in planned
physical and computer-based cognitive training
Unstable medical condition*
Participation in any cognitive training activity
Participation in > 150 min/wk of moderate or greater intensity planned exercise of
any kind
Rapidly progressive or terminal illness
Pre-existing diagnosis of dementia
Psychotic illness (DSM-IV)**
Degenerative neurological disorder
Diagnosis of stroke or TIA
+ within last 12 months, stroke with residual neurological
deficit, two or more strokes or TIAs at anytime, One stroke or TIA with residual
deficits that preclude participation.
TBI
± within past year, or with residual deficits that preclude participation.
Diagnosis of depression (DSM-IV) GDS
++ >9 or current treatment with antidepressant
medications, greater than 3 episodes of depression in the last 5 years ("episode":
requiring treatment), > 10 episodes requiring treatment over lifetime, past suicide
attempts, current bipolar diagnosis and treatment, > 3 past episodes requiring
treatment in last 5 years.
Current alcohol or drug abuse (DSM-IV)
Unrepaired abdominal or other known aneurysm
Myocardial infarction or cardiac surgery within past 6 months
NYHA Class IV CHF
±±
Unstable angina or uncontrolled malignant arrhythmias at rest or on exercise stress
testing
Recent retinal haemorrhage or detachment/proliferative retinopathy
Seizures (>2 in past 12 months)
* Examples of unstable conditions include uncontrolled arrhythmias, hypertension, hyperglycemia, symptomatic enlarging hernia, acute pulmonary embolism,
deep venous thrombosis, recent or unstable fracture, inflammatory or traumatic joint injuries, etc. Such individuals may become eligible if medical or surgical
treatment stabilizes their condition.
^ MMSE Mini Mental Status Examination
27
^^ CDR Clinical Dementia Rating
26
#TICS Telephone Interview for Cognitive Status -Modified
30
**DSM-IV Diagnostic and Statistical Manual of Mental Disorders 4
th edition
+ TIA Trans Ischemic Attack
± TBI Traumatic brain Injury
++ GDS Geriatric Depression Scale [49]
±±NYHA Class IV CHF New York Heart Association Class IV Class of Heart Failure indicating symptoms evident at rest with any physical activity increasing
symptoms, precluding ability to complete physical activity and causing severe limitations.
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quiz control group in a 1:1:1:1 ratio. Flow of subjects
through the study to date is presented in Figure 3.
Stratification
Stratification by gender and age group (55-74; 75+) is
carried out, in anticipation of the greater prevalence of
women in the targeted cohort, and potential age effects
on adaptation to training.
Blinding
Subjects are informed that they will be randomly
assigned to one of four treatment groups by the recruit-
ment officer, and will be blinded to the investigators’
72 hours
72 hours
96 hours
96 hours
1 week (minimum) Next week Baseline
6 Months
18 Months
Monday
Monday Tuesday Friday
Monday Tuesday Friday
Thursday
(or later)
Thursday
(or later)
Thursday
(or later)
Friday
1 week
Figure 2 SMART assessment schedule.
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Page 6 of 15hypothesis as to which is the preferred intervention arm.
All groups will have an equal volume and frequency of
contact with trainers over the 18 months of the study.
All primary and secondary outcomes will be obtained
and analyzed by blinded assessors on different days to
the training programs.
Interventions
All participants complete two group training sessions
per week (total 26 weeks), under the supervision of
trainers. Each session lasts 90 minutes and comprises
approximately 45 minutes PRT or sham physical exer-
cise (sham physical) and 45 minutes CT or sham cogni-
tive exercise (sham CT). In order to take advantage of
the enhanced attention and learning exhibited after an
acute bout of exercise in both animal and human stu-
dies [34], but not enhance adaptation to sham cognitive
training, PRT will proceed CT, and will follow sham CT.
Within each small group (maximum 10) participants
follow the program tailored to their individual
Randomisation n=76
Cognitive (CT) and 
Progressive 
Resistance
Training (PRT) n=20
Did not start n=0
PRT and sham 
Cognitive (SCOG)
n= 17
Did not start n=1
CT and 
Sham physical 
(SPEX)  n=18
Did not start n=0
SCOG and SPEX
n=20
Did not start n=0
Recruitment  Pool n=1926
Assessment for eligibility n=154
Baseline Assessment n=78
Withdrawals n=0
On hold n=2
Ineligible n=44
On hold n=21
Withdrawals n=11
Ineligible n=46
On hold n=155
Not interested n=1510
No contact n=61
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PRT and SCOG 
n=6
Discontinued n=0
Lost n=0
PRT and SCOG
interventions  n=12
Discontinued n=1
Adverse events n=0
CT and SPEX
n=6
Discontinued n=0
Lost n=0
CT and SPEX
Interventions n=15
Discontinued n=1
Adverse events n=0
SCOG and SPEX
n=8
Discontinued n=0
Lost n=0
SCOG and SPEX 
n=17
Discontinued n=1
Adverse events n=0
Drop out n=2
Figure 3 Participant flow through SMART to date.
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Page 7 of 15functioning level, with constant oversight by trainers.
Make-up sessions are allowed for participants who miss
CT and PRT sessions to achieve as close to 52 (26 × 2)
sessions as possible within the 26 week intervention per-
iod. Each training group will have 1-2 trainers present at
the session. The background of the trainers is in exer-
cise physiology or physiotherapy, and the specific tech-
niques of CT and PRT to be administered are learned
from the investigators of this study (NG, MV, MFS).
Throughout the 18- month trial participants are pro-
vided with log books to document their social and
recreational activities per day and are called weekly for
telephone administration of a health status checklist. At
the completion of the 6- month intervention partici-
pants are not given ongoing access to the training or
advice as to what to do. Following assessments at 6 and
18 months participants receive a token reward (movie
tickets or store voucher) for their participation.
Cognitive Training Intervention (+ Sham physical)
Cognitive training (CT) intervention involves computer-
based multimodal and multi-domain exercises targeting
memory, executive function, attention and speed of infor-
mation processing. The training uses the COGPACK
program [35], developed for neuro-rehabilitation and
used in a previous research trial with MCI [36]. A total
set of 14 exercises have been selected including six tasks
of visual and verbal explicit memory (’Reading’, ‘Memory
for names’, ‘Memory for shopping list’, ‘Memory for
forms’, ‘Memory for route’, ‘Memory for traffic signs’),
four tasks of executive function (’Anagrams’, ‘Sequence’,
‘Logic blocks’, ‘Logic’) and four attention and speed tasks
(’Reaction’, ‘Connect’ UFOs’ and ‘Search’). The training
schedule was pre programmed with 4 exercises being
administered at each 45-minute training session. Train-
ing sessions are completed in a group setting with up to
10 computer work stations, and simple touch screens to
avoid training difficulties in the computer-naïve.
Progressive Resistance Training (+ Sham cognitive)
Progressive resistance training (PRT) is supervised by
experienced research assistants (exercise physiologists and
physiotherapists) in a medically-supervised clinic (Univer-
sity of Sydney Health Sciences) at a ratio of 1 trainer for 4-
5 subjects. The specifics of the high intensity training
intervention are summarised in Table 2. Participants are
progressed continuously throughout the 6-month inter-
vention, guided by daily ratings of perceived exertion (15-
18 on the Borg Scale [37] and 1RM’se v e r y3w e e k st o
maintain intensity at 3% from 80 to 92% of current maxi-
mum capacity). Maximization of potential cognitive-
enhancing effects of the PRT is supported by introduction
of novel exercise after every 8 sessions and encouraging
visualisation, counting out loud, and imagery of the mus-
cle repetitions contracting during rest intervals.
Combined CT and PRT
This group will receive both the cognitive training inter-
vention and progressive resistance training intervention,
delivered on the same day within 90-minute sessions.
Sham Cognitive and Sham Physical Exercise Control Group
In this group, subjects will receive versions of cognitive
and physical exercise that are considered to be ineffec-
tive with regards to the cognitive, neurological and phy-
sical outcomes of this trial. The total session length will
be 90 minutes, and all training will be supervised in
groups of up to 10.
Sham Cognitive
Sham CT involves video exposure to a variety of general
interest documentary topics, such as travel, culture, and
history (National Geographic), and tailored to suit the
audience and their expectation of training, are followed
by a set of simple questions regarding the presented
Table 2 Progressive Resistance Training Methodology
Exercise Equipment Frequency Volume Intensity progression
Routine Seated Chest press Digital K400 Keiser pneumatic resistance
machines (Keiser Sports health
Equipments, Inc. Fresno, CA)
2 sessions/
wk
3 sets of
8 per
session
80% of the most recently measured 1RM
progressed each session s tolerated using RPE*
15-18 (approximately 3% per session)
Seated leg press
Seated row
Standing hip
abduction
Knee extension
Novel Lateral raise Free weights (dumbbells) 4 weeks or
8 sessions
3 sets of
8 per
session
15-18 RPE
Hip flexion Keiser
Calf raise Keiser
Hip extension Keiser
Bicep curls Free weights (dumbbells)
*RPE Ratings of perceived Exertion Borg Scale [37]
Gates et al. BMC Geriatrics 2011, 11:19
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trol condition [38] with minimal impact on cognitive
outcomes.
Sham Physical
Sham physical exercise (Sham physical) will include
stretching and seated calisthenics designed so as not to
notably increase heart rate or aerobic capacity, improve
balance, or enhance strength. No use of equipment and
no progression will be included. This regime allows for
maintenance of the double blind design as it is similar
to what older adults anticipate receiving in senior
group exercise classes. Furthermore, in contrast to
aerobic activity, such a regimen has been shown
recently to have no effects on brain volume in older
adults [18].
Adverse Events
Monitoring of adverse events will be achieved by weekly
questionnaire/interview- and proxy information will be
obtained whenever necessary to minimize missing data.
Adverse events will include any exacerbation of underly-
ing disease, or new onset musculoskeletal, cardiovascu-
lar, or metabolic abnormality attributed directly to study
protocols.
Table 3 Primary and secondary cognitive and functional outcome measures
Outcome
measure
Explanation Description
Primary
Cognitive
Alzheimer’s Disease Assessment Scale
(ADAS-Cog) [25]
This subscale of the ADAS, measures severity of cognitive dysfunction associated with
Alzheimer’s disease and is widely used in pharmacological studies of dementia and MCI
[51]. The ADAS-Cog has excellent psychometric properties being valid and reliable, and
is endorsed as a standard outcome measure [26].
Primary
Functional
Bayer-Instrumental Activities of daily Living
(B-ADL) [26,52]
The B-IADL initially developed for pharmaceutical clinical trials to assess deficits in the
activities of daily life in community-dwelling individuals with MCI and response to
pharmacological agents [26], is a 25-item informant or proxy questionnaire.
Secondary
Cognitive
Mini-Mental State Examination (MMSE)[29] Internationally known brief measure to screen for cognitive impairment [41], with valid
and reliable quantitative assessment of severity of cognitive impairment, and is sensitive
to changes in cognitive function over time [53].
GP-Cog [54] Six item self report scale identifying whether patients have greater difficulty functioning
in 6 areas of daily life compared to their level of functioning 5-10 years earlier.
Clinical Dementia Rating (CDR) [28] A commonly used clinical tool for the global assessment of dementia severity, is
completed by a clinician after synthesizing information obtained from the patient,
informants and any other sources [28].
Subjective Memory Complaint (SMC) Eight questions were developed to measure SMC including type of memory difficulty,
concern level, duration, comparison to peers, and reported by informant, meeting
criteria for the assessment of SMC [55].
Life Experience Questionnaire (LEQ)[19] Questionnaire is a self report questionnaire examining the amount and quality of mental
activity a person has engaged in over their life time [19].
Matrices Matrices, a perceptual subtest of the Wechsler Adult Intelligence Scale-III (WAIS-III)
assesses executive functions and requires visual perception, organization, and synthesis
of visual spatial information [56].
Similarities This verbal subtest from the WAIS-III is used to measure verbal conception formation
and abstraction [56].
Trail Making Test (TMT)[40] A and B Trials A and B test speed of attention, sequencing and visual search, and includes a
motor response component, whilst B also assesses mental flexibility, an executive
function [57].
Logical Memory The Logical Memory subtest of the Wechsler Memory Scale 3
rd edition (WMS-III) is used
to measure both immediate and delayed memory for verbal information.
Benton Visual Retention Test (BVRT)[42] This widely used visual memory test assesses visual perception and visual constructive
abilities as participants are required to draw from memory simple designs [41].
Symbol Digit Modalities Test (SDMT) SDMT, first published in 1973 by Aaron Smith and subsequently revised in 1982[41]
measures divided attention, visual scanning, tracking, and motor speed. It uses a
substitution format presenting symbols with matching numbers, and participants are
required to name the numbers corresponding to each given symbol.
Category Fluency Category Verbal Fluency measures verbal production of animal names from semantic
memory [58].
Controlled Oral Word Association Test
(COWAT)
COWAT is a language based task assesses association fluency, and is often used as a
measure of executive functioning. The most commonly used letters are F. A. S. or C. F.
and L. based upon word prevalence rates [58].
Memory Awareness Rating Scale-Memory
Functioning (MARS-MF) [43]
The MARS-MF is an 11 item self report rating scale of everyday memory functioning.
Ratings are made on a 0 - 4 scale where 0 = never and 4 = always, and is usually
administered in an interview format [43].
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Page 9 of 15Specific adverse events that will be routinely monitored
include: falls, cardiac events during physical testing and
exercise training (angina, arrhythmias, blood pressure
excursions, clinically significant ECG changes); fatigue and
muscle soreness or musculoskeletal injury after resistance
or sham physical training; anxiety during MRI scan or cog-
nitive or sham cognitive training; pain or injury related to
movement of ferromagnetic devices, implants, shrapnel
during MRI scan; and pain, bruising, or infection at the
venipuncture site. In addition, subjects will be asked to
report all changes in medication, health care professional
visits, new diagnoses, acute illnesses, or any new symptoms.
Outcome Measures
All outcome measures (see Tables 3, 4, 5, 6 and 7) will
be administered by blinded assessors at baseline, 6
months and at 18 months follow-up. Each test is chosen
because of excellent psychometric properties and mini-
mal sensitivity to practice effects. Cognitive testing takes
place in a fed state (after breakfast), and before any phy-
sical testing on that day to standardize known effects of
fasting and acute exercise on cognitive performance.
Primary outcomes
Cognitive function is measured via the Alzheimer’sD i s -
ease Assessment Scale-Cognitive (ADAS-Cog) [25], and
capacity to perform daily tasks by the Bayer-Activities of
Daily Living (B-IADL) [26] which has been found to dif-
ferentiate between normal ageing and mild to moderate
dementia [39].
Secondary Outcomes
Cognitive function Global cognitive function is assessed
via the Clinical Dementia Rating scale (CDR) [28], and
Mini-Mental Status Examination (MMSE) [29]. Specific
cognitive functions are assessed by Trail Making Test A
and B [40], Matrices and Similarities subtests of the
Wechsler Adult Intelligence Scale 3
rd Edition (WAIS-
III), Symbol Digit Modalities Test (SDMT) [41], Logical
Memory I and II subtests of the Wechsler Memory
Scale 3
rd Edition (WMS-III), Benton Visual Retention
Test-Revised 5
th Edition (BVRT-R) [42] and verbal flu-
ency (Controlled oral words association test, and animal
names). Subjective perception of memory capacity is
assessed by the Memory Functioning Scale of the Mem-
ory Awareness Rating Scale (MARS-MFS) [43]. Cogni-
tive domain scores will be calculated on the basis of
sum of z-scores of index tests, referenced to whole-
group baseline results.
Psychosocial and quality of life Psycho-social well-
being and quality of life are assessed via the Life Satis-
faction Scale (LSS) [44], Physical and Mental Health
Short-36 (SF-36>)[45], Quality of Life Scales (QOLS)
[46], Scale of Psychological Well Being (SPWB) [47],
Depression, Anxiety, Stress Scales (DASS) [48], the Ger-
iatric Depression Scale (GDS) [49], and Duke Social
Support (DSS) [50].
Physical status and level of functional capacity Physi-
cal status and exercise capacity are assessed across
seven domains: body composition; cardio vascular pro-
file; exercise capacity; functional performance; nutri-
tional status; health status; and inflammatory and
anabolic profile, with measures described in Table 4.
Neuroimaging MRI data are acquired at baseline, 6
months follow up and 18 months follow up, using a 3.0-
Tesla Philips Achieva System (see Table 7). For each
Table 4 Secondary outcome measures continued: Psycho-social status
Outcome
Measure
Name of scale Description
Psycho-
social
Geriatric Depression Scale (GDS)
15-items [49]
The GDS is used to assess an older person’s level of depression with simple yes/no response set
[59], and the fifteen item screening test has been reported to be satisfactory [49].
Depression Anxiety and Stress
Scale 21(DASS) [60]
21-item self-report measure of severity of depression, anxiety, and stress psychological symptoms.
Overall Distress can be calculated by summing each of the sub-scale scores with possible scores
ranging from 0-63, with higher scores indicating higher distress [48].
Scale of Psychological Wellbeing
(SPWB) [47]
The SPWB measures well-being and psychological functioning includes six subscales: autonomy;
environmental mastery; personal growth; positive relations with others; purpose in life; and self-
acceptance [47]. Participants are required to rate agreement on a six point agreement scale, with
higher scores indicating greater wellbeing.
Duke Social Support (DSS)[50] The DSS is used to assess perceived adequacy and size of social support network on a 3 point scale
with higher total scores reflecting higher levels of social support [50].
Quality of
life
Life satisfaction Scale (LSS)[44] This single item 7 point delighted-terrible rating scale provides a gestalt measure of life satisfaction,
and can yield reliable and valid data [61].
Physical and Mental Health
Summary Scales (SF36)
®
The Physical & Mental Health Summary Scales include eight generic health concepts, selected from
40 included in the Medical Outcomes Study (MOS), and MOS researchers selected and adapted
questionnaire items and developed new measures for a 149-item Functioning and Well-Being
Profile [62] the source for SF-36
® items.
Quality of Life Scales (QoLS)[46] This 16 item 7 Likert type delighted-terrible self report scale measures satisfaction with five
conceptual aspects of life notably material and physical wellbeing; relationships with other people,
social, community and civic activities; personal development and fulfilment; and recreation [46].
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Page 10 of 15time point, brain structure is assessed using a T1-
weighted whole brain scan (sequence: T1TFE; TR/TE:
6.39/2.9 ms; slice thickness 1.0 mm without gap; field of
view: 256 × 256; resolution 1 × 1 mm) and a T2 FLAIR
scan (sequence: TIR; resolution: 0.488 × 0.488 × 3.5
mm; TR/TE = 10,000/110 ms).
1H-MRS follows in two
volumes of interest: left hippocampus (20 mm M/L, 15
mm D/V, 30 mm A/P, oriented along the hippocampus)
and posterior cingulate grey matter (20 mm M/L, 20
mm D/V, 20 mm A/P) using the PRESS sequence (TE/
TR = 30/2000 ms, 1024 points, 256 averages). Finally, a
resting state functional MRI is conducted using T2*
echo-planar BOLD sequence (TR/TE = 2000/30 ms, 200
volumes) with the subject’s eyes closed.
Covariates
Covariates specified a priori are age, gender, educational
history, occupational history, burden of chronic disease
(medications and diagnoses), nutritional supplements,
history of weight loss in past year and habitual physical
activity level.
Statistical Analysis
We will use an intention to treat (ITT) analytic strategy as
our primary analytic treatment of the data. However, we
acknowledge the potential bias of any method of imputa-
tion [last observation carried forward (LOCF), mean of
group, expectation maximization algorithm (EM)] or
restriction to observed cases (complete case analysis).
Table 5 Secondary outcome measures continued: physical health and functional status
Outcome
Measure
Explanation Description
Body
composition
Anthropometrics Standing height body weight, waist circumference are obtained in triplicate after 12 hour fasting and
body mass index (BMI)) is calculated as fasting body weight (weight kg/height m
2).
Bioelectrical Impedance
Analysis (BIA)
Whole-body skeletal muscle mass (kg) (SMM)* and fat free mass (kg) (FFM) ** were calculated using the
average resistance and reactance values of three sequential BIA measures using the BIA Analyser (RLJ
Prizum, S/N: B10875E, Mode; BIA-101S).
Cardio-
vascular
Pulse Wave Analysis Pulse Wave Velocity (PWV) Pulse Wave Analysis (PWA) Heart Rate Variability (HRV) is determined using
the SphygmoCor Unit and SphygmoCor software.
Ankle Brachial Index (ABI) Clinton MI) Ankle-brachial index (mean of dorsalis pedis and posterior tibialis/brachial BP in both arms).
Blood Pressure (BP) Orthostatic hypotension (OH) Orthostatic Blood Pressure Measurement is taken in a fasted state and
after rising from a five minute rest in supine position. Twenty-four hour ambulatory BP monitoring,
awake and nocturnal means and circadian rhythm are also obtained.
Exercise
Capacity
Muscle strength and
endurance
Maximal strength measurement will be obtained using the digital K400 Keiser pneumatic resistance
machines (Keiser Sports health Equipments, Inc. Fresno, CA). See table 7 for details.
6 minute walk distance
(6MWD) [63]
Walking endurance was assessed using the six minute walk test which is a proxy for overall
cardiovascular endurance capacity (aerobic capacity) and in the elderly subject it may be determined by
muscle strength and endurance, balance, orthopaedic or neurologic abnormalities, and other problems
[63].
Aerobic Capacity Maximal exercise capacity assessed on treadmill walking test (stress test).
Physical
performance
Gait speed habitual and
fast
Habitual and maximal gait velocities is assessed for 2 m (Ultra-timer: Raymar, Oxfordshire, UK) with the
average of two times taken as habitual (CV = 8.7%) and maximal (CV = 7.6%) gait velocity respectively.
Gait analysis (Gait Logger) Participants walk two walks of 2 minute duration and data is recorded using the gait logger Minion
EGaitLogger and downloaded
Isometric handgrip
strength
Isometric handgrip strength of the non dominant hand is assessed using a JAMAR handgrip
dynamometer (Sammons Preston, Bolingbrook, IL)
Chair stand [64] This test is used as a proxy for lower extremity power, or the ability to generate high forces rapidly,
with participants primarily utilising the hip extensor and knee extensor muscle groups [64].
Static Balance Static balance is assessed up to 15 seconds in five different positions (feet apart in parallel stance, feet
together in parallel stance, half tandem stance, tandem stance, and one legged stance), without the use
of assistive device with eyes open. Total static balance is calculated by summing the time recorded for
each of the six stances[65].
Tandem walk Subjects complete a 3 meter forward tandem walk along a marked course with and without a cognitive
distracter task (verbal fluency)
Stair climb The purpose of this test is to climb stairs as rapidly as possible to enable the calculation of Power
(Watts). Power is calculated from the formula: P (watts) = (M × D) × 9.8/t Where: M = Body mass (kg), D
= Vertical distance (m), t = Time (s) and, D = vertical height of the staircase = height of 1 step in
meters × number of steps (if they are all the same height).
*Skeletal muscle mass (SMM) = 0.401(height in cm
2/resistance in ohms)+3.825 (sex: male = 1; female = 0)+age in years(-0.071) + 5.102 [66]
**Fat-free mass (FFM) = -4.03 + 0.734 (height in cm
2/resistance in ohms) +0.116(body weight in kg) + 0.096 (reactance in ohms) +0.984 (sex: male = 1; female =
0)[67]
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dropouts by obtaining final measures regardless of inter-
vention participation or compliance, and will use the EM
method for data missing at random. In addition, we will
compare characteristics of dropouts to completers and
perform secondary sensitivity analyses (completers, and
per-protocol analyses) to examine potential for dropouts
and imputation to bias the results.
Mixed modelling of 6- and 18-month outcomes,
adjusted for baseline values and any potential confoun-
ders identified will be constructed to test our primary
and secondary hypotheses. We will test for main effects
of CT and PRT, as well as for the interaction term (CT
× PRT) to identify isolated and combined training arm
significance and effects sizes. Relationships of interest
and risk factors for changes in cognitive function and
other secondary outcomes will be analysed with simple
and multivariate linear and logistic regression models as
appropriate. Weighted mean differences, 95% Confi-
dence Intervals and Effect Sizes will be calculated for all
outcomes, and clinical meaningfulness will be assessed
in light of available data on the expected annual rates of
change in this cohort for all known primary and second-
ary outcome variables.
Results
We originally estimated the need for a sample size 10%
larger than our expected effect size required (n = 132).
With our retention rate of >90% to date our recruitment
target remains appropriate 120/.90 = 133. Thus, we have
recruited 80/133, 60% of our planned cohort to date.
Compliance with training sessions to date has been high
for all groups with median compliance ranging from
78.44% for sham physical/CT to 100% for PRT/CT.
Furthermore there has been one adverse event reported
thus far (one rotator cuff injury managed conservatively)
in PRT group, and no adverse events during assess-
ments, CT, or sham interventions.
Discussion and conclusions
Recruitment of subjects has been challenging, with less
than 4% of contacts recruited, and 12 telephone screen-
ing interviews required for each subject enrolled. How-
ever, the most common reasons for ineligibility have
been lack of cognitive impairment, or being too physi-
cally active, rather than medical exclusions, attesting to
the potential generalizability of this volunteer sample to
typical older adults with multiple stable chronic illnesses
and mild cognitive impairment.
Table 6 Secondary outcome measures continued: Health status
Outcome measure Explanation Description
Health Status Habitual Physical Activity level Daily physical activity, sedentary behaviour and sleep quality and
quantity are measured with two Actigraph monitors worn for seven
days. The actigraph on the waist measures physical activity and the
wrist sleep quality, with data analysed using the ActilifeGTIM (version
2.2.3) and ActiWebClient (version 4.2.2) programs.
Cortisol Five saliva cortisol samples will be collected using the Salivette
(Sarstedt Aktiengessllschaft and Company; Kirschbaum &
Hellhammer, 1994) and according to manufacturer instructions. A
control ‘resting’“ Pre” and “Post” samples will be taken before
exposure to each ‘stressor’ condition fasting and upon awakening
and 30 minute rest, and a prior to stressor and immediately after the
termination of the stressor condition. The cognitive ‘stressor’
condition is Alzheimer’s Disease Assessment Scale (ADAS-Cog)
assessment during screening and at 6 months assessment
(approximately 45 min), the physical stressor is the second exposure
to a set of maximal strength testing (1RM testing) at baseline and 6
mo.
Medical History Physician complete medical history and physical and neurological
examination.
Inflammatory/Anabolic/
Deoxyribo-Nucleic Acid
(DNA) profile
Serum samples for nutritional, biochemical and
hormonal factors, pro- and anti-inflammatory
cytokines
A venous blood draw is taken after a 12 hour fast for B12, folate,
Thyroid Stimulating Hormone (TSH), insulin, glucose (with calculation
of insulin sensitivity and beta−cell function using the HOMA2
Computer Model), Liver Function Tests (LFT), cholesterol (Total, High
Density Lipoprotein, Low Density Lipoprotein, Triglycerides), Full
blood count, creatinine, albumin, homocysteine, and 25−OH vitamin
D level, and a second sample taken to measure specialist markers of
inflammation: high sensitivity C−reactive protein (hs−CRP), cytokines
InterLeukin (IL)−1b, IL−6, IL−8, IL−10, IL−12p70, IL−18 and Tumor
Necrosis Factor− proteins (TNF-proteins), as well as Brain Derived
Neurotrophic Factor (BDNF), Insulin Growth Factor-1 (IGF-1). At
Baseline only a blood draw is taken for genetic Testing for
Apolipoprotein allele 4 (APOE 4).
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Page 12 of 15Our primary outcomes of global cognitive status and
functional independence are anticipated in 2012. This
information will provide novel and robust evidence for
the efficacy of cognitive and strength training on cogni-
tion and functional status in at risk older adults. This
study conforms to all CONSORT criteria for the report-
ing of RCTs, making it relatively unique in the field to
date. Furthermore, the SMART trial will provide valu-
able information on the persistence of training benefits
after cessation of training at 18 months. Recording par-
ticipant social and recreational activities will also enable
SMART to examine the impact of training post inter-
vention on leisure activity, and control against potential
confounding effects of participants independently pursu-
ing physical exercise and mental activities.
Our secondary outcomes will enable the first compre-
hensive investigation of the relative and combined bene-
fits of physical and cognitive training on brain
morphology and function, anxiety and depressive symp-
toms, self-efficacy, quality of life, body composition, car-
diovascular risk profile, aerobic and musculoskeletal
fitness, and metabolic health. These outcomes will not
only provide evidence of the potentially broad benefits
of the SMART interventions in this cohort, but also
clarify the hypothesized mechanisms contributing to any
observed cognitive outcomes.
In summary, SMART will test a non-pharmacological
preventative intervention that targets older adults at high
risk of cognitive decline. By implementing a regime of
physical and mental exercise, we aim to empower the
individual, contribute to their physical, cognitive and psy-
chological health, and ultimately improve quality of life.
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Table 7 Secondary outcomes continued: neuroimaging
Outcome Measure Description
Structural MRI: T1-
weighted
Whole Brain Measures
1. Voxel Based Morphometry A combination of different software packages will be used for automated and semi-
automated computational neuroanatomical analyses, in addition to expert manual tracing
of hippocampus and entorhinal cortex.
2. Cortical thickness
3. Whole brain volume
4. GM volume
5. WM volume
6. CSF volume
Regional Measures 1. Automated regional cortical
volume measures
2. Manually traced subcortical
volumes
FLAIR-weighted MRI White matter hyperintensity
volume
Automated measure of white matter disease load
Magnetic Resonance
Spectroscopy (MRS)
Relative measures of :
1. N-acetylaspartate (NAA) Measures of different brain metabolites using MR spectroscopy in the hippocampus and
posterior cingulate grey matter.
2. Cholines
3. Myo-inositol
4. Creatine+Phosphocreatine
Resting State functional
MRI
1. Bilateral hippocampal
connectivity
Seed-based correlational analysis and Independent Component Analysis will be used to
characterise individuals’ resting state BOLD time series.
2. Hippocampus functional
connectivity map
3. Posterior cingulate
functional connectivity map
4. Default Mode Network
(DMN)
5. DMN-anticorrelations
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